Leerink Partners Forecasts Strong Price Appreciation for Cencora (NYSE:COR) Stock

Cencora (NYSE:COR) had its target price lifted by stock analysts at Leerink Partners from $388.00 to $405.00 in a note issued to investors on Thursday, Benzinga reports. The firm presently has an “outperform” rating on the stock. Leerink Partners‘s price target points to a potential upside of 21.48% from the company’s previous close.

Other research analysts have also issued research reports about the company. Bank of America lifted their price target on Cencora from $285.00 to $310.00 in a research report on Tuesday, July 21st. Wells Fargo & Company upped their price objective on Cencora from $331.00 to $395.00 and gave the company an “overweight” rating in a research report on Tuesday, August 11th. Citigroup reaffirmed a “buy” rating on shares of Cencora in a research note on Thursday, August 6th. Robert W. Baird lifted their target price on Cencora from $373.00 to $375.00 and gave the stock an “outperform” rating in a report on Thursday, October 22nd. Finally, JPMorgan Chase & Co. lifted their target price on Cencora from $382.00 to $390.00 and gave the stock an “overweight” rating in a report on Friday, August 7th. Thirteen analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $368.73.

Cencora Price Performance

Shares of NYSE COR traded down $6.30 during midday trading on Thursday, reaching $333.38. 1,682,033 shares of the stock traded hands, compared to its average volume of 1,163,722. The company has a debt-to-equity ratio of 3.53, a current ratio of 0.93 and a quick ratio of 0.58. The stock has a market capitalization of $63.62 billion, a PE ratio of 18.60, a P/E/G ratio of 1.73 and a beta of 0.58. Cencora has a one year low of $244.82 and a one year high of $377.54. The company’s 50 day moving average is $325.07 and its 200 day moving average is $317.28.

Cencora (NYSE:COR) last announced its quarterly earnings results on Wednesday, November 4th. The company reported $4.66 earnings per share for the quarter, topping the consensus estimate of $4.58 by $0.08. The company had revenue of $88.35 billion for the quarter, compared to analysts’ expectations of $87.95 billion. Cencora had a net margin of 0.79% and a return on equity of 125.45%. Cencora’s quarterly revenue was up 5.5% on a year-over-year basis. During the same quarter in the previous year, the business posted $3.84 earnings per share. On average, equities research analysts anticipate that Cencora will post 19.58 earnings per share for the current year.

Insider Activity

In related news, EVP Elizabeth Campbell sold 11,300 shares of the business’s stock in a transaction on Monday, August 24th. The stock was sold at an average price of $324.12, for a total transaction of $3,662,556.00. Following the completion of the transaction, the executive vice president owned 19,455 shares in the company, valued at $6,305,754.60. The trade was a 36.74% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.38% of the company’s stock.

Institutional Trading of Cencora

Large investors have recently made changes to their positions in the stock. BlackRock Inc. bought a new stake in Cencora during the 2nd quarter valued at about $5,154,136,000. Bank of America Corp DE grew its stake in Cencora by 6.9% in the 1st quarter. Bank of America Corp DE now owns 4,138,388 shares of the company’s stock worth $1,300,033,000 after acquiring an additional 267,318 shares in the last quarter. Amundi increased its position in shares of Cencora by 43.5% during the second quarter. Amundi now owns 2,229,326 shares of the company’s stock worth $630,855,000 after acquiring an additional 676,066 shares during the period. Carmignac Gestion increased its position in shares of Cencora by 58.7% during the second quarter. Carmignac Gestion now owns 1,747,363 shares of the company’s stock worth $494,463,000 after acquiring an additional 646,112 shares during the period. Finally, Mitsubishi UFJ Asset Management Co. Ltd. bought a new stake in shares of Cencora during the second quarter valued at approximately $483,772,000. 97.52% of the stock is owned by hedge funds and other institutional investors.

Cencora News Roundup

Here are the key news stories impacting Cencora this week:

• Positive Sentiment: Cencora beat quarterly expectations, reporting EPS of $4.66 versus estimates of $4.58 and revenue of $88.35 billion versus $87.95 billion; revenue grew 5.5% year over year. The company also issued a stronger fiscal 2027 earnings outlook, reinforcing expectations for continued growth. Cencora stock enters fiscal 2027 with stronger earnings outlook
• Positive Sentiment: Leerink Partners raised its price target to $405 from $388 and maintained an “outperform” rating, signaling confidence in potential upside.
• Positive Sentiment: Cencora raised its dividend, adding to its appeal for income-focused investors amid market uncertainty. Stocks that hiked dividends
• Neutral Sentiment: The company is realigning its corporate structure. The available report headline does not specify the changes or their expected financial impact. Cencora realigning corporate structure
• Negative Sentiment: Despite Cencora’s earnings beat, shares came under pressure after rival Cardinal Health reported results, prompting concern about relative performance and contributing to a short-term pullback. Cencora drops while rival Cardinal Health posts a beat

About Cencora

Cencora, formerly known as AmerisourceBergen, is a global pharmaceutical services company that connects pharmaceutical manufacturers with healthcare providers. Its core business includes sourcing and distributing medicines and other healthcare products to pharmacies, hospitals, health systems and other care providers.

The company also provides services supporting specialty pharmaceuticals, including logistics, consulting and solutions for manufacturers and healthcare organizations. These services help manage the handling and delivery of complex medicines and support access to treatments.

Cencora serves customers in the United States and internationally.